MARKET

INSM

INSM

Insmed Inc
NASDAQ
72.51
-0.24
-0.33%
After Hours: 72.53 +0.02 +0.02% 19:40 01/17 EST
OPEN
73.50
PREV CLOSE
72.75
HIGH
73.63
LOW
71.50
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
80.53
52 WEEK LOW
21.92
MARKET CAP
12.97B
P/E (TTM)
-13.0526
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on These Healthcare Stocks: UnitedHealth (UNH), Insmed (INSM)
TipRanks · 2d ago
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert
Barchart · 3d ago
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Gilead Sciences (GILD) and Abbott Laboratories (ABT)
TipRanks · 3d ago
Insmed’s Strong Performance and Strategic Developments Drive Buy Rating
TipRanks · 4d ago
How Is The Market Feeling About Insmed?
Benzinga · 6d ago
Noteworthy ETF Outflows: IWM, FTAI, INSM, PCVX
NASDAQ · 6d ago
Insmed (INSM) Gets a Buy from Evercore ISI
TipRanks · 6d ago
Truist Financial Remains a Buy on Insmed (INSM)
TipRanks · 6d ago
More
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Webull offers Insmed Inc stock information, including NASDAQ: INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.